Table 1 Clinical characteristics of AAV patients complicated with or without infection
From: Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study
|  | AAV (n = 248) | Infection group (n = 86) | Non-infection group (n = 162) | P |
|---|---|---|---|---|
Age(ys) | 55.0 (42.8~ 64.0) | 58.0 (46.8~ 66.0) | 54.0 (40.0~ 63.0) | 0.082 |
male, n(%) | 103 (41.5) | 40 (46.5) | 63 (38.9) | 0.155 |
smoke, n(%) | 59 (23.8) | 31 (36.0) | 28 (17.3) | 0.000** |
Diabetes, n(%) | 11 (4.4) | 7 (8.1) | 4 (2.5) | 0.032* |
MPO-ANCA, n(%) | 227 (91.5) | 79 (91.9) | 148 (91.4) | 0.968 |
PR3-ANCA, n(%) | 21 (8.5) | 7(8.1) | 14 (8.6) | 0.968 |
Hemoglobin (g/dl) | 8.5 (7.4~ 9.7) | 8.2 (6.7~ 9.2) | 8.8 (7.7~ 9.9) | 0.004** |
White blood cell (/mm3) | 7200.0 (5000.0~ 10,000.0) | 7600.0 (5900.0~ 11,350.0) | 6900.0 (4900.0~ 9750.0) | 0.049* |
Albumin (g/l) | 35.5 (31.6~ 38.7) | 33.8 (30.3~ 36.9) | 35.9 (32.4~ 39.6) | 0.002* |
Globulin (g/l) | 27.4 (23.4~ 32.2) | 26.8 (22.3~ 33.1) | 27.6 (23.5~ 31.6) | 0.761 |
Creatinine (mg/dl) | 3.3 (1.8~ 5.3) | 4.16 (2.5~ 6.9) | 2.8 (1.5~ 4.7) | 0.000** |
eGFR< 60 ml/min per 1.73m2, n(%) | 216 (87.1) | 81 (94.2) | 135 (83.3) | 0.000** |
CD4 lympnocyte cell(/ul) | 416.0 (234.5~ 589.8) | 399.0 (207.5~ 552.0) | 428.0 (258.0~ 662.0) | 0.027* |
IgG (g/l) | 13.3 (10.4~ 16.4) | 13.4 (10.4~ 16.5) | 12.9 (10.3~ 16.3) | 0.570 |
C3 (g/l) | 0.9 (0.8~ 1.1) | 0.9 (0.8~ 1.2) | 0.9 (0.8~ 1.1) | 0.569 |
Lung involvement, n(%) | 75 (30.2) | 34 (39.5) | 41 (25.3) | 0.011** |
BVAS | 14 (12~ 16) | 15 (12~ 17) | 14 (12~ 16) | 0.009** |
MP pulse therapy, n(%) | 167 (67.3) | 56 (65.1) | 111 (68.5) | 0.929 |
Plasma exchanage, n(%) | 59 (23.8) | 25 (29.1) | 34 (20.9) | 0.109 |
Induction therapy | ||||
 corticosteroids only, n(%) | 65 (26.2) | 25 (29.1) | 40 (24.7) | 0.349 |
 corticosteroids+CYC, n(%) | 66 (26.6) | 26 (30.2) | 44 (27.2) | 0.938 |
 corticosteroids+MMF, n(%) | 77 (31.0) | 26 (30.2) | 47 (29.0) | 0.245 |
 corticosteroids+TW, n(%) | 40 (16.1) | 9 (10.5) | 31 (19.1) | 0.052 |